GeoVax Labs, Inc.

Good day and welcome to the Geofacts Second Quarter 2021 Corporate Update Call. I am Grant with Chorus Call and will facilitate today's call. With me are David Dodd, Chairman and CEO, Mark Reynolds, Chief Financial Officer, and Mark Newman, PhD, Chief Scientific Officer. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then 1 on your telephone keypad. To withdraw your question, please press star, then 2. Please note this event is being recorded. I would now like to turn the conference over to Joel Abraham of Core IR, who will provide a forward-looking statement regarding this call and information herein.

Thank you, Grant. Good afternoon, everyone. We'd like to have you please note the following. Certain statements in this presentation may constitute statements within the meaning of the Private Secured Litigation Reform Act. These statements are based on management's current expectations in terms of uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether GeoVax can develop and manufacture its vaccines, with the desired characteristics in a timely manner. GeoVax's vaccines being safe for human use. GeoVax's vaccine effectively preventing targeted infections in humans. GeoVax's vaccines receiving regulatory approvals necessary to be licensed and marketed. GeoVax raises required capital to complete vaccine development. There is development of competitive products that may be more effective or easier to use than GeoVax's products. GeoVax being able to enter into favorable manufacturing and distribution agreements and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth as risk factors in GeoVax's Form 10-K. It's now my pleasure to introduce the Chairman and CEO of GeoVax, David Dodd. David.

Thank you, Jules.